Role of VAD in the initial treatment of multiple myeloma.
Lane
Steven W
SW
Gill
Devinder
D
Mollee
Peter N
PN
Rajkumar
S Vincent
SV
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008297:Male; D009101:Multiple Myeloma / Q000628:therapy*; D012074:Remission Induction; D033581:Stem Cell Transplantation / Q000379:methods; D013792:Thalidomide / Q000008:administration & dosage; D019172:Transplantation Conditioning / Q000379:methods; D014182:Transplantation, Autologous; D014750:Vincristine / Q000008:administration & dosage
D000893:Anti-Inflammatory Agents; D000903:Antibiotics, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D007166:Immunosuppressive Agents; D013792:Thalidomide; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin